Private Placement
Oryzon Genomics
Joint BookrunnerKempen & Co acted as Joint Bookrunner in Oryzon Genomics’ Capital Increase of €20 million
Transaction highlights
- Private Placement of 7,273,000 shares, 15.9% of Oryzon Genomics’ outstanding share count, at a price of €2.75 per share
- Gross proceeds amounted to €20m, which will be used to progress product candidates in central nervous system and oncology indications
- Proceeds are expected to be used for the advancement of clinical programmes including the Phase IIb trial in BPD adult patients to treat agitation‐aggression, the extension of the Phase II trial in acute myeloid leukaemia and the extension of the Phase II trial in small cell lung cancer
- This transaction marks Kempen & Co’s 7th transaction for European life sciences companies since the beginning of 2020 and our first ever transaction for a Spanish life sciences company, underpinning our ambition to work with innovative life sciences companies across all of Europe
Company description
Oryzon is a leading European epigenetics biotechnology company developing a portfolio of products focused on the central nervous system and oncology around LSD1 (the most abundant enzyme in the human frontal cortex). The Company has recorded positive clinical efficacy data in initial trials across all indications that it is targeting. Most recently the Company reported positive efficacy data in acute myeloid leukaemia in June 2020 where their product, iadademstat, in combination with azacitidine in elderly patients demonstrated an overall response rate of 77% (10 out of 13 evaluable patients), of which 60% are in complete remission. Additionally, the Company reported positive data from its aggression study in Alzheimer’s disease in April 2020 which showed that the product is safe and well tolerated and also led to a significant reduction of agitation-aggression after 6 months of treatment. The Company plans to initiate Phase IIb trials with its lead product for the treatment of aggression in borderline personality disorder in Q1 2021.
Background Kempen Life Sciences & Healthcare
Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent, Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia, Co-Manager in the USD 862 million Global Offering by argenx, Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides, Co-Manager in the USD 154 million Global Offering of DBV Therapeutics, Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical, Lead Manager in the USD 557 million Global Offering by argenx, Co-Manager in the USD 79.2 million US Public Offering by Merus, Co-Manager in the USD 57.5 million Capital Increase by ProQR, Co-Manager in the USD 150 million Nasdaq IPO of BioNTech, Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth, Co-Manager in the USD 20 million Global Offering of Celyad, Co-Manager in the USD 582 million NASDAQ IPO of Genmab, Joint Bookrunner in the €116 million Secondary Sale of Fagron shares by Waterland and Baltisse, Joint Bookrunner in the €48.7 million Rights Issue by Transgene and Joint Bookrunner in the SEK 727 million Capital Increase by Oncopeptides.
Contact
Read more on:
Transactions
No transactions found
Accelerated Bookbuild Offering
Initial Public Offering
on Nasdaq
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Capital increase
Private Placement
US Public Offering
Initial Public Offering
US Public Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
Debt financing
US Public Offering
US Public Offering
Green Revolving Credit Facility
Sale to
Combination with
Accelerated Bookbuild Offering
Sale to
Accelerated Bookbuild Offering
Non-listed equity capital raising
Sale of majority stake to
Secondary Sell-Down in Calliditas Therapeutics
Capital increase
Initial Public Offering
Capital Increase
European FinTech
IPO
Accelerated Bookbuild Offering
Private Placement of shares in
Bridge financing
Undisclosed
Initial Public Offering
Rights issue
Accelerated Bookbuild Offering
US Public Offering
Accelerated Bookbuild Offering
US Public Offering
Merger with Arya Sciences Acquisition Corp. and subsequent Nasdaq listing
acquisition of
Initial Public Offering
Private Placement
Private Placement
Accelerated Bookbuild Offering
Global Accelerated Bookbuild Offering
Accelerated bookbuild offering
Sale of 456 unit landmark residential project in prime location The Hague
acquired by
public offer for
Sale and capital increase
and
Sale of Dutch residential development to
Global Offering
Accelerated Bookbuild Offering
Public takeover of
Sale of
to
Accelerated Bookbuild Offering
Capital increase
Global offering
Rights issue
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Acquisition of
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Increase of stake in
Initial Public Offering
Acquisition of
Acquisition of
Acquisition of
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio
to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Public offer for
Fundraise
Accelerated bookbuild offering
Public offer by German ADLER Real Estate
for Israeli
Public offer by German Vonovia
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Sale of 3 German residential portfolios by
to consortium of buyers
Accelerated bookbuild offering
US public offering
Accelerated bookbuild offering
Secondary offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Secondary placement of 9.4% stake in
Public offer by
for
Public offer by German Vonovia
For Austrian Conwert
Secondary placement of 15% stake in
Formation of Passoã joint venture with
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Initial Public Offering
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Rights issue